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Background
Although the link between altered myocardial substrate
selection and impaired function in obesity cardiomyopathy
is unclear, it is likely to involve altered activity of pyruvate
dehydrogenase (PDH), a key regulator of carbohydrate
metabolism. We hypothesised that; 1) obesity would
impair myocardial carbohydrate oxidation, in turn redu-
cing energetic reserve and predisposing to functional
impairment and 2) normalisation of carbohydrate metabo-
lism either pharmacologically or with calorie restriction
would reverse these changes. Unlike traditional methods,
hyperpolarized [13C]pyruvate MR spectroscopy (MRS)
enables repeated in vivo measurement of both cardiac
PDH flux and the first span of the tricarboxylic acid cycle
and is therefore an ideal tool to investigate this question.
Methods
Long Evans rats with high fat diet induced obesity (n=36)
and normal weight controls (n=12) were diet standardised.
We used in vivo hyperpolarized [1-13C] and [2-13C]pyru-
vate MRS (prototype hyperpolarizer, 7T MR system) to
assess carbohydrate metabolism, echocardiography to
assess diastolic function and perfused heart 31P-MRS
(11.7T) to assess myocardial energetics. Two groups of
obese rats were subsequently treated with either calorie
restriction (70% usual intake, 28 days, n=12) or a GLP-1
analogue (Liraglutide 0.5mg/kg twice daily, 7 days, n=12)
to increase carbohydrate metabolism and restudied.
Results
Obese animals demonstrated left ventricular hypertro-
phy and diastolic, but not systolic, dysfunction (E/E’ 26
±1.5 vs 14±0.86, P<0.05). Hyperpolarized 13C-MRS
demonstrated that obesity not only dramatically reduced
myocardial PDH flux (by 40%, P<0.01) but also
increased the normalised rate of 13C label incorporation
into citrate (by 118%, P<0.05) and glutamate (by 54%,
P<0.01) without change in 13C label incorporation into
lactate or acetylcarnitine (P=ns). Obesity impaired the
myocardial energetic state: both the free energy change
of ATP hydrolysis and PCr/ATP ratio were significantly
impaired (by 5% and 13%, respectively, P<0.05 for both).
Obesity significantly increased tissue PDK4 levels
(P<0.05), the major regulator of cardiac PDH. Liraglu-
tide treatment (weight neutral, P=ns versus the same
group pre-treatment) and calorie restriction (leading to
15% weight loss versus age matched controls, P<0.001)
normalised PDH flux, TCA cycle metabolism, myocar-
dial energetics and function (all P<0.05).
Conclusions
In a rodent model of obesity, hyperpolarized 13C-MRS
identified abnormal cardiac metabolic substrate selection
which was associated with abnormal TCA cycle metabo-
lism, impaired high energy phosphorous metabolism and
functional deficit. Normalisation of PDH flux with either
Liraglutide or calorie restriction reversed this energetic
deficit and normalized function, suggesting PDH may be a
novel therapeutic target.
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